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Abstract: Alzheimer’s disease is complex, and it is unlikely that any one single drug or intervention can successfully 
treat it. The implication of nicotinic acetylcholine receptors (nAChR) in Alzheimer’s disease pathogenesis has opened a 
new perspective on finding drugs usable for ameliorating the memory problems associated with AD. By using nAchR 
modulators, the availability of nAChRs for acetylcholine will be increased and the loss of forebrain cholinergic neurons 
associated with AD might be overcome. The  microbial metabolite 6-hydroxy-D-nicotine has the ability to sustain spatial 
memory in rats by lowering the levels of oxidative stress in the brain and modulating the nAChRs function probably by 
binding to a specific site. Its success from a lab chemical to drug depends highly on its stability or shelf life.  We have 
shown that 6-hydroxy-D-nicotine have a more potent antioxidant effect than nicotine when measured as FRAP units. 
Also, the pH stability of  6-hydroxy-D-nicotine is similar to nicotine, the compounds withstanding 48h exposure to pH 




 Alzheimer’s disease (AD) is an irreversible, progressive brain disorder that slowly affects the ability to carry 
out the simplest tasks by destroying memory and thinking skills. The Alzheimer’s association reports in its March 2018 
fact sheet that this disease is the most expensive one in America, costing more than cancer and heart disease. With an 
estimated direct cost to American society of caring for those with AD of $277 bilion (Alzheimer’s disease Association, 
2018), the impact of the  Alzheimer’s disease on the society is undeniable not negligible.  
 Alzheimer’s disease is complex, and it is unlikely that any one single drug or intervention can successfully 
treat it. Current approaches focus on helping people maintain mental function and slow down memory loss. The 
implication of nicotinic acetylcholine receptors (nAChR) in AD pathogenesis (Bencherif and Lippiello, 2010) has opened 
a new perspective on finding drugs usable for ameliorating the memory problems associated with AD. By using nAchR 
modulators, the availability of nAChRs for acetylcholine will be increased and the loss of forebrain cholinergic neurons 
associated with AD might be overcome (Russo et al., 2014). 
 As the nicotine alkaloid is the archetypal nAChR agonist, we have focused on identifying novel derivatives of 
this compound that might have the same nAChRs binding properties  but without the toxic effects of nicotine. In previous 
in silico and in vivo studies, we have shown that the microbial metabolite 6-hydroxy-D-nicotine (6HNic) has the ability to 
sustain spatial memory in rats (Hritcu et al., 2015; Hritcu et al., 2017) by lowering the levels of oxidative stress in the 
brain (Hritcu et al., 2013) and probably by binding to  nAChRs and modulating their function (Mihasan et al., 2013). 
Moreover,  as the 6-hydroxy-D-nicotine  is a metabolic intermediate found to be accumulating in the growth media of  
Paenarthrobacter nicotinovorans pAO1+ when grown on nicotine (Boiangiu et al., 2014),  a working methodology for 
production of 6HNic with higher yield has been developed (Mihalache et al., 2016). Not only that 6HNic has some 
potential as a neuroprotective drug, but also a feasible biotechnology for its production has been established  making the 
compound highly attractive. Still, two key issues with high impact on 6HNic practical applications remain unsolved. First 
is the half time and toxicology of the compound in plasma and second is its shelf live. The current work tackles on the 
second issue and uses nicotine as a reference substance to compare the in vitro stability of 6HNic at various pHs in 
different aqueous buffers. Supplementary, the antioxidant potential of 6HNic was also assayed and compared with the 
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MATERIAL AND METHODS 
 
Chemicals. All chemicals were purchased from well-known suppliers and were of greatest purity available unless 
otherwise stated 6HNic was a kind gift from Prof. Dr. Roderich Brandsch and was obtained by chemical synthesis. Pure 
6HNic was kept at 4oC. 
Stability assay. 0.05% nicotine and 6HNic were prepared in buffer solutions with the following pHs: 3, 5, 7, 9, 13. For 
pH 3, 5, 7; 50mM citric acid/ citrate buffer was used. For pH 9 a 50 mM TRIS was employed and for pH 13 a 50mM 
boric acid/borate buffer was prepared.  All samples were prepared simultaneously and incubated at room temperature for 
48 h. The pH of the samples was periodically monitored and no significant changes were observed. At precise time 
intervals, samples were taken and frozen at -20oC until further analysis.  
Analytical methods. Nicotine and 6HNic levels were assayed using an RP-HPLC based method described previously 
(Boiangiu et al., 2014). Briefly, an Shimadzu Prominence HPLC system equipped with an auto-sampler, an DAD detector 
and a Machery-Nagel Nucleodur RP C18 ec column (150x4.6 mm, particle size 3µm) incubated at 30oC was used. 20 μL 
of sample was injected and isocratic elution for 10 min with 1 mM H2SO4 : methanol 75:25 at room temperature was used 
for separation. Nicotine levels were monitored at 250 nm and 6HNic levels at 290 nm. Peak hight and peak area were 
used as indications for concentration. 
Antioxidant power of nicotine and 6HNic was compared using the ferric reducing ability of  plasma  or the FRAP Assay 
as described by (Benzie and Strain, 1996). Unlike the original method that uses 10 mM TPTZ as Fe3+ chelator, we used 10 
mM ferrozine (Sodium 4-[3-pyridin-2-yl-5-(4-sulfophenyl)-1,2,4-triazin-6-yl]benzenesulfonate) and the complex was 
measured at 562 nm. OD readings were calibrated using FeSO4 (range 0-75 microM) and FRAP values were expressed as 
microM ascorbic acid.  
Samples were measured in triplicate and standard error was calculated. Statistical significance was assayed using the 
Student-test (p<0,05) performed with Microsoft Excel, Data Analysis Package.  
 
 
RESULTS AND DISCUSSIONS 
 
 6HNic is a better antioxidant then nicotine. By using a round of in-silico docking 
experiments, we have identified the nicotine metabolite 6HNic as a putative ligand for nAChRs 
(Mihasan et al., 2013). The in-vivo tests performed on rats showed that indeed the compound is 
able to improve memory, having the same beneficial effects as nicotine but at a larger extent 
(Hritcu et al., 2017b). Surprisingly, the presence of 6HNic in the brain was associated with an 
decrease of the oxidative stress in rat hippocampus (Hritcu et al., 2013; Hritcu et al., 2015).  This 
could be due to the 6HNic ability to modulate the nAChRs or might be a more direct action of 
6HNic by directly scavenging ROS. The FRAP test is an accepted assay for testing the ability of 
various compounds to function as reductants and to delay or inhibit ROS action on biological 
substrates. Both nicotine and 6HNic were tested for their ability to inhibit the formation of Fe2+ 
from Fe3+ at 3 different concentrations: 15, 30 and 45 microM. In all the conditions tested, 6HNic 
had an better antioxidant potential then nicotine (figure 1). This is actually in good accordance 
with the fact that the  antioxidant activity related to the compound structure is dependable on the 
number of the included active OH or NH2 groups (Bendary et al., 2013). The more active groups 
in the molecule, the more active the compound is.   
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 Figure 1.  6HNic is a better antioxidant then nicotine as shown by the FRAP assay.  
 Nicotine is rather stable at room temperature at pH up to 9. The observed 
neuroprotective effects of 6HNic make this compound very attractive. Moreover, a biotechnology 
is currently developed to produce 6HNic starting from nicotine by using biological conversion 
performed with the help of Paenarthrobacter nicotinovorans cells. The biotechnology developed 
in our lab is using pure nicotine, but several groups from China are working on using toxic 
byproducts and waste water contaminated with nicotine deriving from tobacco industry (Seckar 
et al., 2008) as a nicotine source. Their efforts were successful and two studies report the 
successful production of 6-hydroxy-3-succinoyl-pyridine (Wang et al., 2005) and also 6HNic 
(Yu et al., 2017) from nicotine waste.  
 So not only that 6HNic has some potential as a neuroprotective drug, but it also 
promises a  biotechnology that might convert toxic waste in green chemicals. Its success from a 
lab chemical to drug depends highly on its stability or shelf life. In order to gain some 
information on this issue, we have incubated nicotine and 6HNic for up to 48 hours at room 
temperature and various pHs. At precise time intervals, samples were taken and the levels of 
nicotine and 6HNic were determined using reverse-phase HPLC on a C18 column. No mater 
which buffer was used to control the pH, the obtained chromagrams (Figure 2) allowed us to 
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Figure 2. Typical chromatograms used to quantify A. nicotine and B. 6HNic. 
 
 Apparently, both nicotine and 6HNic are highly stable at pHs ranging from 5 to 9. At pH 
12, both compounds are found at low levels by the HPLC method used (Figure 3). It is not clear 
if the two compounds were affected in terms of chemical modifications or chemical bonds lysis, 
or at pH 12 the compounds are ionized and do not have affinity to the C18 column.  
At pH 3, nicotine appears to be stable for 5 samples, but 6HNic could be detected at low 
concentrations only for the first 2 samples.    




The neuprotective metabolite 6-hyroxy-nicotine is a promising chemical that could be obtained 
by biological transformation of nicotine containing toxic waste. 6HNic proved to have a more 
potent antioxidant effect than nicotine when measured as FRAP units. The pH stability of 6HNic 
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